The research findings were published in the journal Frontiers in Oncology. The randomized, double-blind, placebo-controlled phase II study was supported by a grant from the National Institutes of Health.
“Our results suggest that AHCC® supplementation may help most patients eliminate their HPV infection and reduce the long-term risk of HPV-related cancers,” said Judith A. Smith, PharmD, lead researcher of the study and professor in the department. Obstetrics, Gynecology and Reproductive Sciences at McGovern Medical School at UTHealth Houston. “Through this study as well as several other studies, our research has shown that AHCC supplementation is safe.”
AHCC (active hexose correlated compound) is a proprietary mushroom extract.
The study focused on women with a minimum two-year history of persistent high-risk HPV. Patients in the treatment group received an AHCC supplement for six months, followed by six months of placebo. Patients in the placebo group received a placebo for 12 months. The study found that 14 of 22 patients (63.6%) became HPV-negative in the treatment arm.
HPV is the most common sexually transmitted infection in the United States. According to the Centers for Disease Control and Prevention, there were about 43 million HPV infections in 2018, many of them in their teens and early 20s. HPV infection can cause health problems, including genital warts and cancer. However, HPV vaccines can help eliminate infection and side effects.
“We do not have any other effective treatment for persistent HPV infection other than continuous waiting. Although AHCC supplementation may not help everyone, it is important for patients to ask their physicians to support their immune systems to help overcome persistent HPV infections. readily available to inquire about using it to do. Smith said. (ANI)
First published:June 22, 2022 at 5:21 pm